Elucidation of DPP‐4 involvement in systemic distribution and renal reabsorption of linagliptin by PBPK modeling with a cluster Gauss–Newton method
Abstract The dipeptidyl peptidase‐4 (DPP‐4) inhibitor linagliptin (LNG) exhibits target‐mediated drug disposition (TMDD) in clinical settings, characterized by saturable binding to plasma soluble DPP‐4 (sDPP‐4) and tissue transmembrane DPP‐4 (tDPP‐4). Previous studies have indicated that saturable r...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-10-01
|
| Series: | Clinical and Translational Science |
| Online Access: | https://doi.org/10.1111/cts.70047 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850204992870285312 |
|---|---|
| author | Ryo Nakamura Takashi Yoshikado Yasunori Aoki Yuichi Sugiyama Koji Chiba |
| author_facet | Ryo Nakamura Takashi Yoshikado Yasunori Aoki Yuichi Sugiyama Koji Chiba |
| author_sort | Ryo Nakamura |
| collection | DOAJ |
| description | Abstract The dipeptidyl peptidase‐4 (DPP‐4) inhibitor linagliptin (LNG) exhibits target‐mediated drug disposition (TMDD) in clinical settings, characterized by saturable binding to plasma soluble DPP‐4 (sDPP‐4) and tissue transmembrane DPP‐4 (tDPP‐4). Previous studies have indicated that saturable renal reabsorption of LNG contributes to its nonlinear urinary excretion observed in humans and wild‐type mice, but not in Dpp‐4 knockout mice. To elucidate the mechanisms underlying these complex phenomena, including DPP‐4‐related renal reabsorption of LNG, we employed physiologically‐based pharmacokinetic (PBPK) modeling combined with a cluster Gauss–Newton method (CGNM). The CGNM facilitated the exploration of parameters in rat and human PBPK models for LNG and the determination of parameter identifiability. Through PBPK–CGNM analysis using reported autoradiography data ([14C]‐LNG) in wild‐type and Dpp‐4‐deficient rats, DPP‐4‐specific distributions of LNG in various tissues were clearly differentiated from nonspecific parts. By fitting to human plasma concentrations and urinary and fecal excretions of LNG after intravenous and oral administrations, multiple unknown PBPK parameters were simultaneously estimated by the CGNM. Notably, the amount of tDPP‐4 and the reabsorption clearance for LNG–DPP‐4 complexes were identifiable, indicating their critical role in explaining the complex nonlinear pharmacokinetics of LNG. Compared with previous PBPK analyses, the CGNM allowed us to incorporate greater model complexity (e.g., consideration of tDPP‐4 expressions and in vitro binding kinetics), ultimately resulting in a more accurate reproduction of LNG's TMDD. In conclusion, by considering LNG as a high‐affinity probe for DPP‐4, comprehensive PBPK–CGNM analyses suggested a dynamic whole‐body distribution of DPP‐4, including its involvement in the renal reabsorption of LNG. |
| format | Article |
| id | doaj-art-e6efeaf8ed2c48789699db441dedbad6 |
| institution | OA Journals |
| issn | 1752-8054 1752-8062 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Science |
| spelling | doaj-art-e6efeaf8ed2c48789699db441dedbad62025-08-20T02:11:11ZengWileyClinical and Translational Science1752-80541752-80622024-10-011710n/an/a10.1111/cts.70047Elucidation of DPP‐4 involvement in systemic distribution and renal reabsorption of linagliptin by PBPK modeling with a cluster Gauss–Newton methodRyo Nakamura0Takashi Yoshikado1Yasunori Aoki2Yuichi Sugiyama3Koji Chiba4Laboratory of Clinical Pharmacology Yokohama University of Pharmacy Yokohama‐shi Kanagawa JapanLaboratory of Clinical Pharmacology Yokohama University of Pharmacy Yokohama‐shi Kanagawa JapanLaboratory of Quantitative System Pharmacokinetics/Pharmacodynamics Josai International University Tokyo JapanLaboratory of Quantitative System Pharmacokinetics/Pharmacodynamics Josai International University Tokyo JapanLaboratory of Clinical Pharmacology Yokohama University of Pharmacy Yokohama‐shi Kanagawa JapanAbstract The dipeptidyl peptidase‐4 (DPP‐4) inhibitor linagliptin (LNG) exhibits target‐mediated drug disposition (TMDD) in clinical settings, characterized by saturable binding to plasma soluble DPP‐4 (sDPP‐4) and tissue transmembrane DPP‐4 (tDPP‐4). Previous studies have indicated that saturable renal reabsorption of LNG contributes to its nonlinear urinary excretion observed in humans and wild‐type mice, but not in Dpp‐4 knockout mice. To elucidate the mechanisms underlying these complex phenomena, including DPP‐4‐related renal reabsorption of LNG, we employed physiologically‐based pharmacokinetic (PBPK) modeling combined with a cluster Gauss–Newton method (CGNM). The CGNM facilitated the exploration of parameters in rat and human PBPK models for LNG and the determination of parameter identifiability. Through PBPK–CGNM analysis using reported autoradiography data ([14C]‐LNG) in wild‐type and Dpp‐4‐deficient rats, DPP‐4‐specific distributions of LNG in various tissues were clearly differentiated from nonspecific parts. By fitting to human plasma concentrations and urinary and fecal excretions of LNG after intravenous and oral administrations, multiple unknown PBPK parameters were simultaneously estimated by the CGNM. Notably, the amount of tDPP‐4 and the reabsorption clearance for LNG–DPP‐4 complexes were identifiable, indicating their critical role in explaining the complex nonlinear pharmacokinetics of LNG. Compared with previous PBPK analyses, the CGNM allowed us to incorporate greater model complexity (e.g., consideration of tDPP‐4 expressions and in vitro binding kinetics), ultimately resulting in a more accurate reproduction of LNG's TMDD. In conclusion, by considering LNG as a high‐affinity probe for DPP‐4, comprehensive PBPK–CGNM analyses suggested a dynamic whole‐body distribution of DPP‐4, including its involvement in the renal reabsorption of LNG.https://doi.org/10.1111/cts.70047 |
| spellingShingle | Ryo Nakamura Takashi Yoshikado Yasunori Aoki Yuichi Sugiyama Koji Chiba Elucidation of DPP‐4 involvement in systemic distribution and renal reabsorption of linagliptin by PBPK modeling with a cluster Gauss–Newton method Clinical and Translational Science |
| title | Elucidation of DPP‐4 involvement in systemic distribution and renal reabsorption of linagliptin by PBPK modeling with a cluster Gauss–Newton method |
| title_full | Elucidation of DPP‐4 involvement in systemic distribution and renal reabsorption of linagliptin by PBPK modeling with a cluster Gauss–Newton method |
| title_fullStr | Elucidation of DPP‐4 involvement in systemic distribution and renal reabsorption of linagliptin by PBPK modeling with a cluster Gauss–Newton method |
| title_full_unstemmed | Elucidation of DPP‐4 involvement in systemic distribution and renal reabsorption of linagliptin by PBPK modeling with a cluster Gauss–Newton method |
| title_short | Elucidation of DPP‐4 involvement in systemic distribution and renal reabsorption of linagliptin by PBPK modeling with a cluster Gauss–Newton method |
| title_sort | elucidation of dpp 4 involvement in systemic distribution and renal reabsorption of linagliptin by pbpk modeling with a cluster gauss newton method |
| url | https://doi.org/10.1111/cts.70047 |
| work_keys_str_mv | AT ryonakamura elucidationofdpp4involvementinsystemicdistributionandrenalreabsorptionoflinagliptinbypbpkmodelingwithaclustergaussnewtonmethod AT takashiyoshikado elucidationofdpp4involvementinsystemicdistributionandrenalreabsorptionoflinagliptinbypbpkmodelingwithaclustergaussnewtonmethod AT yasunoriaoki elucidationofdpp4involvementinsystemicdistributionandrenalreabsorptionoflinagliptinbypbpkmodelingwithaclustergaussnewtonmethod AT yuichisugiyama elucidationofdpp4involvementinsystemicdistributionandrenalreabsorptionoflinagliptinbypbpkmodelingwithaclustergaussnewtonmethod AT kojichiba elucidationofdpp4involvementinsystemicdistributionandrenalreabsorptionoflinagliptinbypbpkmodelingwithaclustergaussnewtonmethod |